Olfactory Disorder Clinical Trial
Official title:
Oral and Olfactory Complications of Recovered COVID-19 Patients: A Prospective Cohort Study
NCT number | NCT04791436 |
Other study ID # | OORCV |
Secondary ID | |
Status | Recruiting |
Phase | |
First received | |
Last updated | |
Start date | May 1, 2021 |
Est. completion date | May 28, 2025 |
This cohort study aims to investigate the long-standing chemosensory disorders and oral manifestation after recovery of the COVID-19 illness. A correlation between the long-standing symptoms and the COVID-19 severity grade will be very important to understand and clarify the aetiology of these symptoms.
Status | Recruiting |
Enrollment | 402 |
Est. completion date | May 28, 2025 |
Est. primary completion date | January 30, 2025 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - All adult COVID-19 recovery patients (exceeding the age of 18) will be included in the study. The time between illness and study recruitment shall be at least 3 months. Exclusion Criteria: - Exclusion criteria are psychiatric or neurological diseases, previous trauma, surgery or radiotherapy in the oral or nasal cavities, pre-existing taste or smell dysfunctions or chronic rhinosinusitis. |
Country | Name | City | State |
---|---|---|---|
Germany | Justus-Liebig University | Gießen | Hesse |
Lead Sponsor | Collaborator |
---|---|
University of Giessen | Masaryk University, University of Kiel |
Germany,
Ammar N, Aly NM, Folayan MO, Khader Y, Virtanen JI, Al-Batayneh OB, Mohebbi SZ, Attia S, Howaldt HP, Boettger S, Maharani DA, Rahardjo A, Khan I, Madi M, Rashwan M, Pavlic V, Cicmil S, Choi YH, Joury E, Castillo JL, Noritake K, Shamala A, Galluccio G, Polimeni A, Phantumvanit P, Mancino D, Kim JB, Abdelsalam MM, Arheiam A, Dama MA, Nyan M, Hussein I, Alkeshan MM, Vukovic AP, Iandolo A, Kemoli AM, El Tantawi M. Behavior change due to COVID-19 among dental academics-The theory of planned behavior: Stresses, worries, training, and pandemic severity. PLoS One. 2020 Sep 29;15(9):e0239961. doi: 10.1371/journal.pone.0239961. eCollection 2020. — View Citation
Ammar N, Aly NM, Folayan MO, Mohebbi SZ, Attia S, Howaldt HP, Boettger S, Khader Y, Maharani DA, Rahardjo A, Khan I, Madi M, Shamala A, Al-Batayneh OB, Rashwan M, Pavlic V, Cicmil S, Galluccio G, Polimeni A, Mancino D, Arheiam A, Dama MA, Nyan M, Phantumvanit P, Kim JB, Choi YH, Castillo JL, Joury E, Abdelsalam MM, Alkeshan MM, Hussein I, Vukovic AP, Iandolo A, Kemoli AM, El Tantawi M. Knowledge of dental academics about the COVID-19 pandemic: a multi-country online survey. BMC Med Educ. 2020 Nov 2;20(1):399. doi: 10.1186/s12909-020-02308-w. — View Citation
Attia S, Howaldt HP. Impact of COVID-19 on the Dental Community: Part I before Vaccine (BV). J Clin Med. 2021 Jan 14;10(2):288. doi: 10.3390/jcm10020288. — View Citation
Bottger S, Zechel-Gran S, Streckbein P, Knitschke M, Hain T, Weigel M, Wilbrand JF, Domann E, Howaldt HP, Attia S. A New Type of Chronic Wound Infection after Wisdom Tooth Extraction: A Diagnostic Approach with 16S-rRNA Gene Analysis, Next-Generation Sequencing, and Bioinformatics. Pathogens. 2020 Sep 28;9(10):798. doi: 10.3390/pathogens9100798. — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Periodontal health | Community Periodontal Index (CPI) of the World Health Organization (WHO) will be used to assess periodontal health (continuous variable) | At least 3 months after recovery of COVID-19 | |
Primary | Oral mucocutaneous lesions | An intraoral examination will be carried out to assess the presence of any mucocutaneous lesions (dichotomous variable) | At least 3 months after recovery of COVID-19 | |
Primary | Gustatory function | Burghart Sniffin' Sticks "Screening 12 Test" will be used to assess gustatory function (continuous variable) | At least 3 months after recovery of COVID-19 | |
Primary | Olfactory function | Burghart Sniffin' Sticks "Screening 12 Test" will be used to assess olfactory function (continuous variable) | At least 3 months after recovery of COVID-19 |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04617444 -
The ESTxENDS Trial- Substudy on Effects of Using Electronic Nicotine Delivery Systems (ENDS) on Olfactory Function
|
N/A | |
Completed |
NCT02985515 -
Steroid Nasal Irrigation for Flavor Evaluation and Detection Study
|
N/A | |
Recruiting |
NCT06066307 -
Olfactory Performance in Culinary Arts Students
|
Phase 4 | |
Completed |
NCT05445921 -
Stellate Ganglion Block for COVID-19-Induced Olfactory Dysfunction
|
Phase 1/Phase 2 | |
Recruiting |
NCT05855369 -
Smell Training and Trigeminal Nerve Stimulation for COVID-related Smell Loss
|
Phase 2/Phase 3 | |
Recruiting |
NCT03574701 -
Intranasal Retinoic Acid Treatment for Patients With OlfactoryLOSS: A RANDOMIZED CONTROLLED TRIAL
|
N/A | |
Enrolling by invitation |
NCT04764981 -
Olfactory Training for Olfactory Dysfunction After Coronavirus Disease - 19 (COVID-19)
|
N/A | |
Completed |
NCT03990766 -
Smell Changes & Efficacy of Nasal Theophylline
|
Phase 2 | |
Withdrawn |
NCT05542095 -
Simvastatin Nasal Rinses for the Treatment of COVID-19 Mediated Dysomsia
|
Phase 1 | |
Enrolling by invitation |
NCT05038475 -
Clinical and Immunological Responses After SARS-CoV-2 Infection Causing COVID-19
|
||
Completed |
NCT01332825 -
cAMP (Cyclic Adenosine Monophosphate) Levels in the Nose
|
N/A | |
Completed |
NCT04789499 -
Smell in Covid-19 and Efficacy of Nasal Theophylline
|
Phase 2 | |
Active, not recruiting |
NCT04761458 -
Correlation of Preoperative Global Olfactory Function With Frailty, Perioperative Neurocognitive Disorders and Mortality
|
N/A | |
Completed |
NCT04406584 -
Intranasal Injection of PRP Versus Saline for Treatment of Olfactory Dysfunction
|
N/A | |
Completed |
NCT03611673 -
At-Home Olfactory Training
|
N/A | |
Completed |
NCT04700891 -
Correlation of Preoperative Olfactory Identification Function With Frailty and Postoperative Complications and Mortality
|
N/A | |
Recruiting |
NCT04466982 -
Assessment of Olfactory Dysfunction in SARS CoV-2 (COVID-19) Infection
|
||
Recruiting |
NCT04869436 -
Olfactory Outcomes of Dupilumab Treatment for Nasal Polyposis
|
Phase 4 | |
Recruiting |
NCT05448898 -
The Efficacy of Traditional Chinese Medicine in Olfactory Dysfunction
|
N/A | |
Completed |
NCT04235153 -
CAncer, NUtrition and Taste - Validation of the CANUT-QVA Questionnaire on Eating Habits in Cancer Patients
|